Quanta Therapeutics is a clinical-stage biotechnology company developing novel therapies for the treatment of neurodegenerative diseases. The company's lead product candidate, QUANTA-101, is a small molecule inhibitor of the protein kinase GSK-3β that is currently in Phase 2 clinical trials for the treatment of Alzheimer's disease. Quanta Therapeutics is also developing a pipeline of other potential therapies for the treatment of Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases.